Company: RPTX
Filing Date: 2025-12-03
Form Type: PREM14A
Source: 0001193125-25-306948
Chunk: 34

Company: Repare Therapeutics Inc.
Filing Date: 2025-12-03
Form: PREM14A
Chunk 34
---
 or other nominee and to submit a copy in advance of the meeting. Further instructions will be provided to you as part of your registration process.

15

Internet proxy voting will be provided to allow you to vote your Common shares online, with procedures designed to ensure the authenticity and correctness of your proxy vote instructions. However, please be aware that you must bear any costs associated with your internet access, such as usage charges from internet access providers and telephone companies.

| Q: | Who can attend and vote at the Special Meeting and what is the quorum for the Special Meeting? |

| A: | Registered Shareholders and duly appointed proxy holders can participate in the online Special Meeting and vote                                                                                                                                           
 and ask questions at the appropriate times during the Special Meeting. A quorum for the transaction of business at the Special Meeting is two Persons who are, or who represent by proxy, Shareholders who, in the aggregate, hold Common Shares to which 
 are attached at least 25% of the votes attached to all of the issued Common Shares entitled to voting rights at the Special Meeting. Broker non-votes and proxies marked “ABSTAIN” will be counted                                                        
 for purposes of determining the presence or absence of a quorum for the transaction of business at the Special Meeting.                                                                                                                                   |

| Q: | What will Shareholders receive in the Arrangement? |

| A: | If the Arrangement is completed, Shareholders (other than Shareholders who properly exercise their Dissent                                                                                                                                              
 Rights) will be entitled to receive a cash payment and one CVR per Common Share. The amount of the cash payment is currently estimated to be approximately US $1.82 per Common Share and will be determined finally based upon the Company’s cash       
 balance immediately prior to the Effective Time on the Effective Date after deducting certain transaction costs, the aggregate amount of outstanding liabilities, and a transaction fee to the Purchaser of US$4,000,000. In addition, each Shareholder 
 will also receive one non-transferable CVR for each Common Share that will entitle the holder to receive, following Closing, contingent cash payments equal to:                                                                                         |

| (i). | 100% of certain additional receivables that may be received by the Company within ninety (90) days 
 following Closing (net of certain permitted deductions incurred in connection therewith);          |

| (ii). | a percentage of the net proceeds received from the Company’s existing partnerships with Bristol-Myers                                                                                                                                            
 Squibb, Debiopharm and DCx